Feigen Malcolm, Lee Sze Ting, Lawford Catherine, Churcher Katheryn, Zupan Eddy, Scott Andrew M, Hamilton Chris
Austin Health Radiation Oncology Centre, Heidelberg West Centre for PET Ludwig Institute for Cancer Research Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
J Med Imaging Radiat Oncol. 2011 Jun;55(3):320-32. doi: 10.1111/j.1754-9485.2011.02274.x.
The management of malignant pleural mesothelioma represents one of the most challenging issues in oncology, as there is no proven long-term benefit from surgery, radiotherapy or chemotherapy alone or in combination. Locoregional progression remains the major cause of death, but radical surgical resection may produce major postoperative morbidity. While radical or postoperative radiotherapy using conventional techniques has resulted in severe toxicity with no impact on survival, recent advances in radiotherapy delivery may be more effective.
We treated patients with locally advanced mesothelioma whose tumours had been sub optimally resected with high-dose three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) to large volumes of one hemithorax, using CT and positron emission tomography (PET) scan-based treatment planning. Clinical outcomes were assessed by determining patterns of failure and metabolic changes in total glycolytic volume (TGV) between pre- and post-irradiation( 18) F-FDG PET/CT scans and by recording acute and late toxicity grades.
Fourteen patients were analysed with 40 PET scans performed before and up to 4.5years after radiotherapy. Eleven patients had pleurectomy/decortications, one had an extrapleural pneumonectomy and two had no surgery. Four patients who received chemotherapy had all progressed prior to radiotherapy. After radiotherapy, the in-field local control rate was 71%. No progression occurred in two patients, one was salvaged with further radiotherapy to a new site, four recurred inside the irradiated volume all with concurrent distant metastases and the other seven had distant metastases only. The TGVs were reduced by an average of 67% (range 12-100%) after doses of 45 to 60Gy to part or all of one hemithorax. There were no serious treatment-related toxicities. Median survival was 25months from diagnosis and 17months after starting radiotherapy.
We have established that mesothelioma can be locally controlled with high radiation doses using 3DCRT or IMRT, and that strict normal tissue dose constraints have limited radiation toxicities. Radiotherapy should be considered to prevent or delay the local manifestations of progressive disease in suitable patients after surgery including extrapleural pneumonectomy and pleurectomy/decortication. Higher radiation doses may allow more effective palliation.
恶性胸膜间皮瘤的治疗是肿瘤学中最具挑战性的问题之一,因为单独或联合使用手术、放疗或化疗均未被证明具有长期益处。局部区域进展仍然是主要的死亡原因,但根治性手术切除可能会导致严重的术后并发症。虽然使用传统技术的根治性或术后放疗会产生严重毒性且对生存率无影响,但放疗技术的最新进展可能更有效。
我们对局部晚期间皮瘤患者进行了治疗,这些患者的肿瘤切除不彻底,采用基于CT和正电子发射断层扫描(PET)的治疗计划,对一侧半胸的大体积区域进行高剂量三维适形放疗(3DCRT)或调强放疗(IMRT)。通过确定放疗前后(18)F-FDG PET/CT扫描中失败模式和总糖酵解体积(TGV)的代谢变化,并记录急性和晚期毒性等级来评估临床结果。
对14例患者进行了分析,放疗前及放疗后长达4.5年共进行了40次PET扫描。11例患者接受了胸膜剥脱术/去皮质术,1例接受了胸膜外全肺切除术,2例未接受手术。4例接受化疗的患者在放疗前均已进展。放疗后,野内局部控制率为71%。2例患者无进展,1例通过对新部位进行进一步放疗挽救,4例在照射野内复发且均伴有远处转移,另外7例仅发生远处转移。对一侧半胸的部分或全部区域给予45至60Gy剂量后,TGV平均降低了67%(范围为12%-100%)。没有严重的与治疗相关的毒性反应。从诊断开始的中位生存期为25个月,放疗开始后的中位生存期为17个月。
我们已经证实,使用3DCRT或IMRT高剂量放疗可以局部控制间皮瘤,并且严格的正常组织剂量限制可使放疗毒性有限。对于包括胸膜外全肺切除术和胸膜剥脱术/去皮质术在内的手术后合适患者,应考虑放疗以预防或延迟疾病进展的局部表现。更高的放疗剂量可能会带来更有效的姑息治疗效果。